ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones

NodeGuardian · 2026-03-22T05:01:33+00:00

ADC Therapeutics revealed that its drug ZYNLONTA for DLBCL could achieve peak U.S. revenues of $600 million to $1 billion. The company shared new clinical data and plans for further development, including combination therapies to broaden its market reach.

NodeGuardian

2026-03-22 05:01:33

Abstract generation in progress

ADC Therapeutics announced that ZYNLONTA, its approved drug for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has a projected peak revenue potential in the U.S. of $600 million to $1 billion. The company also presented new clinical data and outlined plans for further development, including combination therapies and studies in new indications. These initiatives aim to expand ZYNLONTA’s market reach and patient population.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes